Received Mar 7, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | 232Z3 | — |
Pediatric dose to an adult patient; Pediatric dose to an adult patient; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of adult use of a child product in a 28-year-old female patient who received HAV (Havrix pediatric) (batch number 232Z3, expiry date 14-NOV-2025) for prophylaxis. On 04-MAR-2025, the patient received the 2nd dose of Havrix pediatric. On 04-MAR-2025, an unknown time after receiving Havrix pediatric, the patient experienced adult use of a child product (Verbatim: Pediatric dose to an adult patient) and underdose (Verbatim: Pediatric dose to an adult patient). The outcome of the adult use of a child product and underdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 05-MAR-2025 The registered pharmacist reported that they had a adult patient came for Havrix vaccine and they were given the 2nd pediatric dose, which led to adult use of a child product and underdose. The Vaccine Administration Facility was the same as Primary Reporter.